|
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with …
The Pharma Letter Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. • COPD (100/25mcg): The … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file next-generation Advair in USA, EU |
View full post on asthma – Google News